References
- Nicolaides KH, Azar G, Bryne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy. BMJ 1992;304:876–879.
- Brambati B, Lanzani A, Tului L. Ultrasound and biochemical assessment of first trimester pregnancy. In: Chapman M, Grudzinskas JG, Chard T, editors. The embryo: normal and abnormal development and growth. New York: Springer-Verlag; 1991. pp 181–194.
- Spencer K, Macri JN, Aitken DA, Connor JM. Free beta-hCG as first-trimester marker for fetal trisomy. Lancet 1992;339:1480.
- Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002;20:219–225.
- Nicolaides KH, Sebire NJ, Snijders RJ. Down’s syndrome screening with nuchal translucency. Lancet 1997;349:438.
- Sepe SJ, Connell FA, Geiss LS, Teutsch SM. Gestational diabetes. Incidence, maternal characteristics, and perinatal outcome. Diabetes 1985;34 Suppl 2:13–16.
- White P. Classification of obstetric diabetes. Am J Obstet Gynecol 1978;130:228–230.
- Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet Gynecol 2003;102:857–868.
- American College of Obstetricians and Gynecologists. Gestational diabetes, Practice bulletin 2000; no. 30.
- Pedersen JF, Sørensen S, Ruge S. Human placental lactogen and pregnancy-associated plasma protein A in first trimester and subsequent fetal growth. Acta Obstet Gynecol Scand 1995;74:505–508.
- Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn 2003;23:990–996.
- Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265–1270.
- Pedersen JF, Sørensen S, Mølsted-Pedersen L. Serum levels of human placental lactogen, pregnancy-associated plasma protein A and endometrial secretory protein PP14 in first trimester of diabetic pregnancy. Acta Obstet Gynecol Scand 1998;77:155–158.
- Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn 2005;25:927–929.
- The Fetal Medicine Foundation. http://www.fetalmedicine.com.
- Deutsche Diabetes-Gesellschaft. Diagnostik und Therapie des Gestationsdiabetes. Richtlinien der Deutschen Diabetes-Gesellschaft (Diagnostic and therapy of GDM, Guidelines from the German Diabetes Association). Frauenarzt 1993;34:13–14.
- Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: Implications for prenatal screening and genetic counseling. Am J Med Genet A 2005;133A:31–36.
- Danilenko-Dixon DR, Van Winter JT, Nelson RL, Ogburn PL Jr. Universal versus selective gestational diabetes screening: application of 1997 American Diabetes Association recommendations. Am J Obstet Gynecol 1999;181:798–802.